ChemoCentryx (CCXI) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChemoCentryx Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 9, 2015 4:07 PM EST-- All patients complete dosing in complement inhibitor CCX168 program for ANCA Associated Vasculitis; Phase II CLEAR clinical trial top-line results anticipated in December or early January --
-- Pancreatic cancer trial of CCX872 shows strong enrollment; Immuno-oncology data and diabetic nephropathy results presentations highlighted at recent national meetings --
-- Conference Call Today at 5:00 p.m. Eastern Time --
MOUNTAIN VIEW, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases,... More
